Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 4
2011 1
2012 5
2013 3
2014 4
2015 9
2016 3
2017 1
2018 1
2019 3
2020 4
2021 4
2022 3
2023 4
2024 6
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. INSIGHT START Study Group, et al. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20. N Engl J Med. 2015. PMID: 26192873 Free PMC article. Clinical Trial.
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.
Ryan P, Blanco JL, Masia M, Garcia-Fraile L, Crusells MJ, Domingo P, Curran A, Guerri-Fernandez R, Bernal E, Bravo J, Revollo B, Macias J, Tiraboschi JM, Montejano R, Amador C, Torralba M, Merino D, Diaz-Brito V, Galindo MJ, Ferra S, Villoslada A, Losa JE, Fanjul FJ, Perez-Stachowski X, Peraire J, Portilla J, de la Fuente S, Dueñas C, Vazquez MJ, Di Gregorio S, Esteban H, Gil P, de Miguel M, Alejos B, Martínez E; PASO-DOBLE study group. Ryan P, et al. Among authors: tiraboschi jm. Lancet HIV. 2025 Jul;12(7):e473-e484. doi: 10.1016/S2352-3018(25)00105-5. Epub 2025 Jun 7. Lancet HIV. 2025. PMID: 40489982 Clinical Trial.
The persistence of low CD4/CD8 ratio in chronic HIV-infection, despite ART suppression and normal CD4 levels, is associated with pre-therapy values of inflammation and thymic function.
Garrido-Rodríguez V, Bulnes-Ramos Á, Olivas-Martínez I, Pozo-Balado MDM, Álvarez-Ríos AI, Gutiérrez F, Izquierdo R, García F, Tiraboschi JM, Vera-Méndez F, Peraire J, Rull A, Pacheco YM; CoRIS cohort. Garrido-Rodríguez V, et al. Among authors: tiraboschi jm. J Microbiol Immunol Infect. 2024 Dec;57(6):854-867. doi: 10.1016/j.jmii.2024.08.007. Epub 2024 Aug 22. J Microbiol Immunol Infect. 2024. PMID: 39209566 Free article.
Early Detection of Cancer and Precancerous Lesions in Persons With HIV Through a Comprehensive Cancer Screening Protocol.
Gutiérrez F, López L, Galera C, Tiraboschi JM, Portu J, García-Fraile L, García Del Toro M, Bernal E, Rivero A, García-Abellán J, Flores J, González-Cordón A, Martínez O, Bravo J, Rosado D, Montero M, Sirera G, Torralba M, Galindo MJ, Macías J, Gónzalez-Cuello I, Boix V, Vivancos MJ, Dios P, Blanco JR, Padilla S, Fernández-González M, Gutiérrez-Ortiz de la Tabla A, Martínez E, Masiá M; IMPAC-Neo Study Group. Gutiérrez F, et al. Among authors: tiraboschi jm. Clin Infect Dis. 2025 Feb 24;80(2):371-380. doi: 10.1093/cid/ciae359. Clin Infect Dis. 2025. PMID: 38959300 Free PMC article.
Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size.
De La Torre Tarazona E, Moraga E, Vaquer R, Sánchez-Palomino S, de Lazzari E, Luna L, Vicens-Artés S, García Fraile LJ, Peraire J, Garcia-Gasalla M, Balsalobre L, Guillén Martínez S, López Cortés LF, Jarrín I, Serrano-Villar S, Alcamí J, Moreno S; CoRIS Cohort. De La Torre Tarazona E, et al. Sci Rep. 2025 Jul 13;15(1):25306. doi: 10.1038/s41598-025-09474-1. Sci Rep. 2025. PMID: 40653494 Free PMC article.
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.
Suárez-García I, Alejos B, Moreno C, Martín Torres J, Masiá M, García-Fraile LJ, Riera M, Dalmau D, Rodríguez-Rosado R, Muga R, Moreno S, Jarrín I; CoRIS cohort. Suárez-García I, et al. J Antimicrob Chemother. 2025 Mar 3;80(3):682-691. doi: 10.1093/jac/dkae456. J Antimicrob Chemother. 2025. PMID: 39710424 Free PMC article.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
62 results